Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success

Haematologica

Volumn 86, Issue 11, 2001, Pages 1186-1193

  Mariana, G ^a   Kroner, B ^a   Miller, R T ^a   Ewing, N P ^a   Butler, R ^a   Morfini, M ^a   Bell, B ^a   Fressinaud, E ^a   Gringeri, A ^a   Kisker, C T ^a   Kessler, C ^a   Gill, J C ^a   Scharrer, I ^a   Arcieri, P ^a   Zimmermann, R ^a   White, G C ^a   Mariani, G ^a   Growe, G H ^a   Di Michele, D ^a   Nagao, T ^a   Brackmann, H H ^a   Mauser Bunschoten, E P ^a   Balocchi, A ^a   Thompson, A R ^a   Inwood, M J ^a   Brettler, D B ^a   Magallon Martinez, M ^a   Scheibel, E ^a   Beardsley, D S ^a   Menza, L ^a   Mancc Johnson, M ^a   Tusell, J ^a   Chiu Poon, M ^a   Walker, I ^a   Rodeghiero, F ^a   Bond, M ^a   Rasi, V ^a   Sultan, Y ^a   Rubin, S H ^a   Blei, F ^a   Guerois, C ^a   Ciavarella, N ^a   Berrettini, M ^a   Peerlinck, K ^a   Lusher, J ^a   Wicklund, B M ^a   Lenk, H ^a   Goudemand, J ^a   Ekert, H ^a   Korper, M A ^a   D'Oiron, R ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

FVIII; FVIII alloantibodies; FVIII inhibitors; Immune tolerance

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMOPHILIA; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; ISOANTIBODIES; MIDDLE AGED; PROGNOSIS;

EID: 0035170866     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli
2. The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies
3. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products
4. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
5. Massive factor-VIII infusion in haemophiliacs with factor-VIII inhibitor, high responder
6. Induced immunotolerance in factor VIII inhibitor patients
7. Immune tolerance for the treatment of factor inhibitors: Twenty years' "Bonn protocol"
8. Induction of immune tolerance in haemophilia A inhibitor patients by the "Bonn Protocol": Predictive parameter for therapy duration and outcome
9. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors
10. Disappearance of FVIII:C antibodies in patients with hemophilia A upon frequent administration of factor VIII in intermediate or low dose
11. The importance of corticoids added to continuous treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A
12. Induction of immunetolerance for high-titre inhibitor eradication: A long-term follow-up
13. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII
14. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX
15. Immune tolerance in hemophilia-principal results from the International Registry
16. A more uniform measurement of factor VIII inhibitors
17. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A
18. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance
19. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients
20. Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation
21. Immune tolerance induction: A role for recombinant activated factor VII (rFVIIa)?
22. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy
23. Treatment of patients with factor VIII and IX inhibitors with special focus on the use of recombinant factor VIIa
24. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: Current practice implications
25. The German National Immune Tolerance Registry, 1997 update
26. Comparison of the international immune tolerance registry and the North American immune tolerance registry
27. Immune tolerance in hemophilia and inhibitors: A cost analysis
28. Pharmaco-economic aspects of inhibitor treatment
29. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada
30. Economic aspects of haemophilia care in the United States
31. Immune tolerance in hemophilia and treatment of hemophiliacs with an inhibitor
32. Meeting report. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor